# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louis Chen initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Overweight rating.
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target f...
Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and raises the price target...
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting so...
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.14) per share. This is a 133.33 percent decrease over los...
Oppenheimer analyst Jeff Jones reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $1.2 price ta...
Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that...